Abstract : In later years the rate of expanded spectrum beta lactamase-producing microbes has gotten progressively high causing difficulty in the treatment choices. The current study attempted to identify the predominance of extended-spectrum beta-lactamases among Escherichia coli confines from different clinical samples. A prospective investigation was conducted over a duration of 6 months. Throughout the December 2023–May 2024 study period, about 70 non-repetitive clinical segregates of Escherichia coli from various clinical samples (urine, blood, pus, & other body fluids) were taken into consideration. Their Antimicrobial susceptibility patterns were noted and later inoculated on ESBL base agar. MIC detection was done by an E-test. The double disc synergy test, which uses combination discs containing clavulanic acid and cephalosporin, was used to validate the ESBL phenotypic detection. Of the 70 confines, 36(51.4%) were extended-spectrum beta-lactamase makers and 8(22.2%) segregates among them were multidrug-resistant Escherichia coli. Urine samples accounted for 41.4% the majority followed by exudates and blood. Majority of the isolates were sensitive to Meropenem followed by piperacillin tazobactam and Imepenem. According to the study's findings, there is a high prevalence of ESBL generation, which calls for the use of appropriate antimicrobial treatments and contamination control procedures.

Keyword : Drug resistance, E.coli, Extended-spectrum betalactamases, gram negative bacteria.